iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. pozri časti 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
defibrilátor kardioverter platinium crt d1711 / platinium crt d1741 / platinium 4lv crt d1744
microport crm s.r.l. via crescentino s.n. 130 40 saluggia (vc) taliansko -
defibrilátor kardioverter platinium sonr crt d1811 / platinium sonr crt d1841 / platinium 4lv sonr crt d1844
microport crm s.r.l. via crescentino s.n. 130 40 saluggia (vc) taliansko -
defibrilátor kardioverter platinium dr1510 / platinium dr 1540
microport crm s.r.l. via crescentino s.n. 130 40 saluggia (vc) taliansko -
defibrilátor kardioverter platinium vr1210 / platinium vr1240
microport crm s.r.l. via crescentino s.n. 130 40 saluggia (vc) taliansko -
prokanazol 100 mg
exeltis slovakia s.r.o., slovensko - itrakonazol - 26 - antimycotica (lokÁlne a celkovÉ)
sporanox
johnson & johnson, s.r.o., slovensko - itrakonazol - 26 - antimycotica (lokÁlne a celkovÉ)